Cited by 548Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchNeurological disorders and treatments

DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers

Open access
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W. +24 more·2007·Neurology

Abstract

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of alpha-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal alpha-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of alpha-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for alpha-synuclein pathologies; 4) accelerated efforts to find more…

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000256715.13907.d3

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., Fahn, S., Farmer, J. M., Galasko, D., Galvin, J. E., Goetz, C. G., Growdon, J. H., Gwinn-Hardy, K. A., Hardy, J., Heutink, P., Iwatsubo, T., Kosaka, K., Lee, V. M.-Y., Leverenz, J. B., Masliah, E., McKeith, I. G., Nussbaum, R. L., Olanow, C. W., Ravina, B. M., Singleton, A. B., Tanner, C. M., Trojanowski, J. Q., & Wszolek, Z. K.
Affiliations
  • Drexel University (US)
  • University of Pennsylvania (US)
  • Stavanger University Hospital (NO)
  • Hammersmith Hospital (GB)
  • Sorbonne Université (FR)
  • Istanbul University (TR)
  • Columbia University (US)
  • University of California San Diego (US)
  • Washington University in St. Louis (US)
  • Rush University (US)
  • Harvard University (US)
  • Vrije Universiteit Amsterdam (NL)
  • The University of Tokyo (JP)
  • Yokohama City University (JP)
  • Newcastle University (GB)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Rochester (US)
  • National Institutes of Health (US)
Venue
Neurology
Published
2007-03-13
Volume
68
Issue
11
Pages
812-819
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2077398422
Cited by
548
References
2
Citations by year
2026: 7 · 2025: 17 · 2024: 14 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 23 · 2019: 31 · 2018: 24 · 2017: 23 · 2016: 34 · 2015: 29 · 2014: 32 · 2013: 28 · 2012: 41
FWCI
35.45
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • National Institutes of Health (1r13ns054546-01)
  • National Institute on Aging (AG09215, P30AG010124, P01AG009215, AG-10124)
  • National Institute of Neurological Disorders and Stroke (NS054546-01)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
dementia with Lewy bodies, Parkinson's disease dementia, Lewy body disease, alpha-synuclein, Lewy body pathology, diagnostic criteria, disease-modifying therapy, biomarkers, neurodegeneration, autopsy confirmation
MeSH terms
Humans, Parkinson Disease, Biomarkers, Lewy Body Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review